Recent News

Jan

06

FPI-2068 IND expected to be submitted in the first quarter of 2023 FPI-1434 Phase 1 data expected in the second quarter of 2023 FPI-1966 Phase 1 study open and enrolling patients; Company expects...

Jan

05

- Agreement augments Fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows - Furthers BWXT Medical's position as a global leader in medical...

Jan

04

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the...

View All

Overview

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus fermentum urna dictum sem sollicitudin fringilla. Donec porttitor tristique congue. Vestibulum congue cursus nunc, at convallis augue pulvinar sit amet. Maecenas interdum rhoncus ullamcorper. Aliquam maximus purus in sapien bibendum, ac pulvinar ipsum venenatis. Praesent maximus sapien rhoncus massa tincidunt pretium. Vivamus ornare sem vitae purus efficitur luctus. Maecenas feugiat a lorem sit amet dignissim. Vestibulum varius tincidunt lobortis. Nulla maximus, nisi vitae tempus gravida, urna metus placerat diam, luctus mollis justo augue vel enim. Mauris condimentum convallis diam, eget sodales enim egestas sollicitudin. Donec vitae maximus risus, et euismod risus. Aliquam erat volutpat. Phasellus ultricies ac turpis nec dignissim. In auctor augue massa, vulputate ullamcorper ipsum ultricies non.

Stock Information
NASDAQFUSN
NEVER MISS AN UPDATE